{"id":"https://openalex.org/W3133430707","doi":"https://doi.org/10.1158/1078-0432.ccr-20-2399","title":"Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22","display_name":"Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22","publication_year":2021,"publication_date":"2021-02-18","ids":{"openalex":"https://openalex.org/W3133430707","doi":"https://doi.org/10.1158/1078-0432.ccr-20-2399","mag":"3133430707","pmid":"https://pubmed.ncbi.nlm.nih.gov/33602684"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-20-2399","doi":"https://doi.org/10.1158/1078-0432.ccr-20-2399","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-2399","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/27/10/2742/3082772/2742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/clincancerres/article-pdf/27/10/2742/3082772/2742.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["1MD Anderson Cancer Center, University of Texas, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, University of Texas, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005939966","display_name":"Wendy Stock","orcid":"https://orcid.org/0000-0002-8349-9200","observed_orcids":["https://orcid.org/0000-0002-8349-9200"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Stock","raw_affiliation_strings":["2University of Chicago, Chicago, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Chicago, Chicago, Illinois","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071844603","display_name":"Ryan Daniel Cassaday","orcid":"https://orcid.org/0000-0002-3424-2425","observed_orcids":["https://orcid.org/0000-0002-3424-2425"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan D. Cassaday","raw_affiliation_strings":["3University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, Washington"],"raw_orcid":"https://orcid.org/0000-0002-3424-2425","affiliations":[{"raw_affiliation_string":"3University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, Washington","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. DeAngelo","raw_affiliation_strings":["4Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0001-7865-2306","affiliations":[{"raw_affiliation_string":"4Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049385583","display_name":"Elias Joseph Jabbour","orcid":"https://orcid.org/0000-0003-4465-6119","observed_orcids":["https://orcid.org/0000-0003-4465-6119"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elias Jabbour","raw_affiliation_strings":["1MD Anderson Cancer Center, University of Texas, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, University of Texas, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006104041","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0002-2481-7504","observed_orcids":["https://orcid.org/0000-0002-2481-7504"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan M. O'Brien","raw_affiliation_strings":["5Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006288618","display_name":"Matthias Stelljes","orcid":"https://orcid.org/0000-0002-9331-5145","observed_orcids":["https://orcid.org/0000-0002-9331-5145"]},"institutions":[{"id":"https://openalex.org/I4210103666","display_name":"University Hospital M\u00fcnster","ror":"https://ror.org/01856cw59","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210103666"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Matthias Stelljes","raw_affiliation_strings":["6Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany","institution_ids":["https://openalex.org/I4210103666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115695385","display_name":"Tao Wang","orcid":"https://orcid.org/0009-0003-1825-0163","observed_orcids":["https://orcid.org/0009-0003-1825-0163","https://orcid.org/0000-0002-5910-8775"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tao Wang","raw_affiliation_strings":["7Pfizer Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Pfizer Inc., Cambridge, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010946186","display_name":"Maria Luisa Paccagnella","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Luisa Paccagnella","raw_affiliation_strings":["8Pfizer Inc., Groton, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Pfizer Inc., Groton, Connecticut","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086592810","display_name":"Kevin T. Nguyen","orcid":"https://orcid.org/0000-0001-9102-6537","observed_orcids":["https://orcid.org/0000-0001-9102-6537"]},"institutions":[{"id":"https://openalex.org/I4405268496","display_name":"Navigate BioPharma (United States)","ror":"https://ror.org/015hykp02","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Nguyen","raw_affiliation_strings":["9Navigate BioPharma Services, Inc., a Novartis subsidiary, Carlsbad, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Navigate BioPharma Services, Inc., a Novartis subsidiary, Carlsbad, California","institution_ids":["https://openalex.org/I4405268496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112427303","display_name":"Barbara Sleight","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Sleight","raw_affiliation_strings":["8Pfizer Inc., Groton, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Pfizer Inc., Groton, Connecticut","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009581524","display_name":"Erik R. Vandendries","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erik Vandendries","raw_affiliation_strings":["7Pfizer Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Pfizer Inc., Cambridge, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081736171","display_name":"Alexander Neuhof","orcid":"https://orcid.org/0000-0002-7926-2593","observed_orcids":["https://orcid.org/0000-0002-7926-2593"]},"institutions":[{"id":"https://openalex.org/I4210100293","display_name":"Pfizer (Germany)","ror":"https://ror.org/00m8w3m39","country_code":"DE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210100293"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Alexander Neuhof","raw_affiliation_strings":["10Pfizer Pharma GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Pfizer Pharma GmbH, Berlin, Germany","institution_ids":["https://openalex.org/I4210100293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087379820","display_name":"Alexander Laird","orcid":"https://orcid.org/0000-0002-7296-025X","observed_orcids":["https://orcid.org/0000-0002-7296-025X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Douglas Laird","raw_affiliation_strings":["11Pfizer Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Pfizer Inc., San Francisco, California","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082944296","display_name":"Anjali S. Advani","orcid":"https://orcid.org/0000-0003-0015-5902","observed_orcids":["https://orcid.org/0000-0003-0015-5902"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali S. Advani","raw_affiliation_strings":["12Cleveland Clinic, Cleveland, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Cleveland Clinic, Cleveland, Ohio","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5090435894"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":4.5335,"has_fulltext":true,"cited_by_count":56,"citation_normalized_percentile":{"value":0.9584531,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"27","issue":"10","first_page":"2742","last_page":"2754"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-acute-lymphoblastic-leukemia","display_name":"relapsed/refractory acute lymphoblastic leukemia","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6460000276565552},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8149999976158142},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8809999823570251},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9599999785423279},{"id":"https://openalex.org/keywords/remission-duration","display_name":"remission duration","score":0.7950000166893005},{"id":"https://openalex.org/keywords/hepatobiliary-adverse-events","display_name":"hepatobiliary adverse events","score":0.7519999742507935},{"id":"https://openalex.org/keywords/hematological-adverse-events","display_name":"hematologic adverse events","score":0.7490000128746033},{"id":"https://openalex.org/keywords/cytogenetics","display_name":"cytogenetics","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C111700020","wikidata":"https://www.wikidata.org/wiki/Q5009798","display_name":"CD22","level":4,"score":0.8427664041519165},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7772760987281799},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7186585664749146},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6149851083755493},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.5389881730079651},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44535237550735474},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35887622833251953},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.34390872716903687},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.15235069394111633},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.1084565818309784},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.058960020542144775},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004198","descriptor_name":"Disease Susceptibility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019468","descriptor_name":"Disease Management","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051918","descriptor_name":"Sialic Acid Binding Ig-like Lectin 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-20-2399","doi":"https://doi.org/10.1158/1078-0432.ccr-20-2399","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-2399","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/27/10/2742/3082772/2742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:33602684","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33602684","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.ccr-20-2399","doi":"https://doi.org/10.1158/1078-0432.ccr-20-2399","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-2399","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/27/10/2742/3082772/2742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3133430707.pdf","grobid_xml":"https://content.openalex.org/works/W3133430707.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W1488000644","https://openalex.org/W1600925615","https://openalex.org/W1879221139","https://openalex.org/W1943300686","https://openalex.org/W1970050467","https://openalex.org/W1991294485","https://openalex.org/W2057680307","https://openalex.org/W2066508515","https://openalex.org/W2075099666","https://openalex.org/W2082189475","https://openalex.org/W2083001039","https://openalex.org/W2117663747","https://openalex.org/W2120853229","https://openalex.org/W2126855868","https://openalex.org/W2150648608","https://openalex.org/W2167213955","https://openalex.org/W2321589388","https://openalex.org/W2329186770","https://openalex.org/W2330814896","https://openalex.org/W2419639370","https://openalex.org/W2517195212","https://openalex.org/W2525034031","https://openalex.org/W2587240909","https://openalex.org/W2725721905","https://openalex.org/W2725970815","https://openalex.org/W2730231599","https://openalex.org/W2752517775","https://openalex.org/W2783032930","https://openalex.org/W2886906891","https://openalex.org/W2891679914","https://openalex.org/W2896845000","https://openalex.org/W2922526548","https://openalex.org/W2931981435","https://openalex.org/W2990115538","https://openalex.org/W3029132671","https://openalex.org/W3211488171","https://openalex.org/W7075666251"],"related_works":["https://openalex.org/W2908388890","https://openalex.org/W2983236679","https://openalex.org/W4281683246","https://openalex.org/W4225329131","https://openalex.org/W2606353108","https://openalex.org/W2907699286","https://openalex.org/W4409984251","https://openalex.org/W3096739793","https://openalex.org/W3029132671","https://openalex.org/W2789502283"],"abstract_inverted_index":{"PURPOSE:":[0],"We":[1],"assessed":[2],"the":[3,164,196,233],"relationship":[4,192],"between":[5,195],"cluster":[6],"of":[7,13,18,37,50,84,137,166,170,198],"differentiation-22":[8],"(CD22)":[9],"expression":[10,228],"and":[11,45,89,126,140,157,179,200,203,220,229],"outcomes":[12],"inotuzumab":[14,75,97,120,147,186,236],"ozogamicin":[15,76,98,121,187,208,237],"versus":[16,77,99,122,188,214],"standard":[17],"care":[19],"(SC)":[20],"in":[21,101,134,154,216],"INO-VATE":[22],"(NCT01564784).":[23],"PATIENTS":[24],"AND":[25],"METHODS:":[26],"=":[27],"162).":[28],"Outcomes":[29],"were":[30,93,117,132,177],"analyzed":[31],"by":[32],"baseline":[33],"CD22":[34,40,46,63,104,110,138,141,155,167,204,222,227],"positivity":[35,64,105,111,142,156],"(percentage":[36],"leukemic":[38],"blasts":[39],"positive,":[41],"\u226590%":[42],"vs.":[43],"<90%)":[44],"receptor":[47,158],"density":[48,159],"[molecules":[49],"equivalent":[51],"soluble":[52],"fluorochrome":[53],"(MESF),":[54],"quartile":[55,135],"analysis].":[56],"RESULTS:":[57],"Most":[58],"patients":[59,102,108,149,217],"had":[60,109],"high":[61,226],"(\u226590%)":[62],"per":[65,143],"central":[66],"laboratory.":[67,145],"The":[68],"response":[69,115],"rate":[70,182],"was":[71,160,183,193],"significantly":[72,94],"higher":[73,118,184,219],"with":[74,96,103,119,150,218,225],"SC.":[78,189],"Minimal/measurable":[79],"residual":[80],"disease":[81],"negativity,":[82],"duration":[83],"remission":[85],"(DoR),":[86],"progression-free":[87],"survival,":[88],"overall":[90],"survival":[91],"(OS)":[92],"better":[95],"SC":[100,215],"\u226590%.":[106],"Fewer":[107],"<90%;":[112],"for":[113,185],"whom,":[114],"rates":[116,197],"SC,":[123],"but":[124,162],"DoR":[125],"OS":[127],"appeared":[128],"similar.":[129],"Similar":[130],"trends":[131],"evident":[133],"analyses":[136],"MESF":[139],"local":[144],"Among":[146],"ozogamicin-responding":[148],"subsequent":[151],"relapse,":[152],"decrease":[153],"evident,":[161],"not":[163],"emergence":[165],"negativity.":[168],"Rates":[169],"grade":[171],"\u22653":[172],"hematologic":[173,199],"adverse":[174],"events":[175],"(AEs)":[176],"similar":[178],"hepatobiliary":[180],"AEs":[181,202],"No":[190],"apparent":[191],"observed":[194],"hepatic":[201],"expression.":[205,223],"CONCLUSIONS:":[206],"Inotuzumab":[207],"demonstrated":[209],"a":[210],"favorable":[211],"benefit-risk":[212],"profile":[213],"lower":[221],"Patients":[224],"normal":[230],"cytogenetics":[231],"benefited":[232],"most":[234],"from":[235],"therapy.":[238]},"counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-03-01T00:00:00"}